All Title Author
Keywords Abstract

Gold Standard Program for Heavy Smokers in a Real-Life Setting

DOI: 10.3390/ijerph10094186

Keywords: smoking cessation, abstinence, heavy smokers, intensive program, nationwide database, group program, individual program, Denmark

Full-Text   Cite this paper   Add to My Lib


Background: High-intensity smoking cessation programs generally lead to more continuous abstinence, however, lower rates of success have been reported among heavy smokers. The aim was to evaluate continuous abstinence among heavy smokers during the intensive 6-week Gold Standard Program (GSP) and to identify modifiable factors associated with continuous abstinence. Methods: In this nationwide clinical study based on 36,550 smokers attending an intensive cessation program in Denmark. Heavy smoking was defined as ≥7 points in the Fagerstr?m Nicotine Dependency Test, smoking ≥20 cigarettes daily or ≥20 pack-years. Results: Overall, 28% had a Fagerstr?m score ≥7 points, 58% smoked ≥20 cigarettes daily and 68% smoked ≥20 pack-years. Continuous abstinence was 33% in responders (6-months response rate: 78%); however, abstinence was approximately 1–6% lower in the heavy smokers than the overall population. Attending GSP with an individual format ( vs. group/other, OR 1.23–1.44); in a hospital setting ( vs. pharmacy/municipality services, OR 1.05–1.11); and being compliant (attending the planned meetings OR 4.36–4.89) were associated with abstinence. Abstinence decreased in a dose-dependent manner with increasing smoking severity. Conclusions: Abstinence after GSP was 1–6% lower in the heavy smokers than in the overall study population. Modifiable factors may be used for small improvements in continued abstinence. However attempts to improve compliance seemed especially promising.


[1]  World Health Organization. WHO Report on the Global Tobacco Epidemic, 2011 Warning about the Dangers of Tobacco; World Health Organization: Geneva, Switzerland, 2011.
[2]  Tobacco Use and Dependence Guideline Panel. Treating Tobacco Use and Dependence: 2008 Update; US Department of Health and Human Services: Washington, DC, USA, 2008.
[3]  Kamholz, S.L. Pulmonary and cardiovascular consequences of smoking. Med. Clin. N. Am. 2004, 88, 1415–1430, doi:10.1016/j.mcna.2004.07.008.
[4]  Heatherton, T.F.; Kozlowski, L.T.; Frecker, R.C.; Fagerstr?m, K.O. The fagerstr?m test for nicotine dependence: A revision of the fagerstr?m tolerance questionnaire. Br. J. Addict. 1991, 86, 1119–1127, doi:10.1111/j.1360-0443.1991.tb01879.x.
[5]  Bierut, L.J. Nicotine dependence and genetic variation in the nicotinic receptors. Drug Alcohol Depend. 2009, 104, S64–S69, doi:10.1016/j.drugalcdep.2009.06.003.
[6]  Olsen, K.R.; Bilde, L.; Juhl, H.H.; Kjaer, N.T.; Mosbech, H.; Evald, T.; Rasmussen, M.; Hiladakis, H. Cost-effectiveness of the Danish smoking cessation interventions: Subgroup analysis based on the Danish Smoking Cessation Database. Eur. J. Health Econ. 2006, 7, 255–264, doi:10.1007/s10198-006-0362-1.
[7]  Kjaer, N.T.; Evald, T.; Rasmussen, M.; Juhl, H.H.; Mosbech, H.; Olsen, K.R. The effectiveness of nationally implemented smoking interventions in Denmark. Prev. Med. 2007, 45, 12–14, doi:10.1016/j.ypmed.2007.04.001.
[8]  Daughton, D.; Susman, J.; Sitorius, M.; Belenky, S.; Millatmal, T.; Nowak, R.; Patil, K.; Rennard, S.I. Transdermal nicotine therapy and primary care. Importance of counseling, demographic, and participant selection factors on 1-year quit rates. The Nebraska Primary Practice Smoking Cessation Trial Group. Arch. Fam. Med. 1998, 7, 425–430, doi:10.1001/archfami.7.5.425.
[9]  Herrera, N.; Franco, R.; Herrera, L.; Partidas, A.; Rolando, R.; Fagerstr?m, K.O. Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. Chest 1995, 108, 447–451, doi:10.1378/chest.108.2.447.
[10]  Lind, M.; Jaspers, K. Manual for Smoking Cessation in Groups, 2nd ed. ed.; Danish Cancer Association: Copenhagen, Denmark, 2008.
[11]  Peng, R.; Wang, S. Nicotine sublingual tablet for smoking cessation in 115 cases: A double-blind randomized placebo-controlled clinical trial. J. Clin. Rehabil. Tissue Eng. Res. 2007, 11, 10443–10446.
[12]  Pisinger, C.; Vestbo, J.; Borch-Johnsen, K.; J?rgensen, T. It is possible to help smokers in early motivational stages to quit. The Inter99 study. Prev. Med. 2005, 40, 278–284.
[13]  Baker, T.B.; Piper, M.E.; McCarthy, D.E.; Bolt, D.M.; Smith, S.S.; Kim, S.-Y.; Colby, S.; Conti, D.; Giovino, G.A.; Hatsukami, D.; et al. Time to first cigarette in the morning as an index of ability to quit smoking: Implications for nicotine dependence. Nicot. Tob. Res. 2007, 9, S555–S570, doi:10.1080/14622200701673480.
[14]  Kozlowski, L.T.; Porter, C.Q.; Orleans, C.T.; Pope, M.A.; Heatherton, T. Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, and HSI. Drug Alcohol Depend. 1994, 34, 211–216, doi:10.1016/0376-8716(94)90158-9.
[15]  Ferguson, J.; Bauld, L.; Chesterman, J.; Judge, K. The English smoking treatment services: One-year outcomes. Addiction 2005, 100, 59–69, doi:10.1111/j.1360-0443.2005.01028.x.
[16]  Stead, L.F.; Perera, R.; Bullen, C.; Mant, D.; Lancaster, T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 2008, 23, doi:10.1002/14651858.CD000146.pub3.
[17]  Lai, D.T.; Cahill, K.; Qin, Y.; Tang, J.-L. Motivational interviewing for smoking cessation. Cochrane Database Syst. Rev. 2010, 20, doi:10.1002/14651858.CD006936.pub2.
[18]  Lancaster, T.; Stead, L.F. Individual behavioural counselling for smoking cessation. Cochrane Database Syst. Rev. 2005, 18, doi:10.1002/14651858.CD001292.pub2.
[19]  Stead, L.F.; Lancaster, T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst. Rev. 2005, doi:10.1002/14651858.CD001007.
[20]  Thomsen, T.; Villebro, N.; M?ller, A.M. Interventions for preoperative smoking cessation. Cochrane Database Syst. Rev. 2010, 20, doi:10.1002/14651858.CD002294.pub2.
[21]  Lancaster, T.; Stead, L.F. Physician advice for smoking cessation. Cochrane Database Syst. Rev. 2004, 18, doi:10.1002/14651858.CD000165.pub2.
[22]  Stead, L.; Lancaster, T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. Cochrane Database Syst. Rev. 2012, 12, doi:10.1002/14651858.CD009670.pub2.
[23]  WHO Collaborating Centre—Smoking Cessation Database. Available online: (accessed on 17 October 2011).
[24]  M?ller, A.M.; Villebro, N.; Pedersen, T.; T?nnesen, H. Effect of preoperative smoking intervention on postoperative complications: A randomised clinical trial. Lancet 2002, 359, 114–117, doi:10.1016/S0140-6736(02)07369-5.
[25]  T?nnesen, H. Surgery and smoking at first and second hand. Anesthesiology 2011, 115, 1–3, doi:10.1097/ALN.0b013e31822085f3.
[26]  Rasmussen, M.; Ammari, A.B.H.; Pedersen, B.; T?nnesen, H. Smoking cessation intervention activities and outcome before, during and after the national Healthcare Reform in Denmark. Clin. Health Promot. 2012, 2, 26–35.
[27]  Neumann, T.; Rasmussen, M.; Ghith, N.; Heitmann, B.L.; T?nnesen, H. The Gold Standard Programme: Smoking cessation interventions for disadvantaged smokers are effective in a real-life setting. Tob. Control 2012, doi:10.1136/tobaccocontrol-2011-050194.
[28]  West, R.; Hajek, P.; Stead, L.; Stapleton, J. Outcome criteria in smoking cessation trials: Proposal for a common standard. Addiction 2005, 100, 299–303, doi:10.1111/j.1360-0443.2004.00995.x.
[29]  Bauld, L.; Bell, K.; McCullough, L.; Richardson, L.; Greaves, L. The effectiveness of NHS smoking cessation services: A systematic review. J. Public Health 2010, 32, 71–82.
[30]  Simon, J.A.; Carmody, T.P.; Hudes, E.S.; Snyder, E.; Murray, J. Intensive smoking cessation counseling vs. minimal counseling among hospitalized smokers treated with transdermal nicotine replacement: A randomized trial. Am. J. Med. 2003, 114, 555–562, doi:10.1016/S0002-9343(03)00081-0.
[31]  Hiscock, R.; Judge, K.; Bauld, L. Social inequalities in quitting smoking: What factors mediate the relationship between socioeconomic position and smoking cessation? J. Public Health 2011, 33, 39–47, doi:10.1093/pubmed/fdq097.
[32]  Lemmens, V.; Oenema, A.; Knut, I.K.; Brug, J. Effectiveness of smoking cessation interventions among adults: A systematic review of reviews. Eur. J. Cancer Prev. 2008, 17, 535–544, doi:10.1097/CEJ.0b013e3282f75e48.
[33]  Mottillo, S.; Filion, K.B.; Bélisle, P.; Joseph, L.; Gervais, A.; O’Loughlin, J.; Paradis, G.; Pihl, R.; Pilote, L.; Rinfret, S.; et al. Behavioural interventions for smoking cessation: A meta-analysis of randomized controlled trials. Eur. Heart J. 2009, 30, 718–730.
[34]  Bauld, L.; Coleman, T.; Adams, C.; Pound, E.; Ferguson, J. Delivering the English smoking treatment services. Addiction 2005, 100, 19–27.
[35]  Christen, A.G.; Christen, J.A. The female smoker: From addiction to recovery. Am. J. Med. Sci. 2003, 326, 231–234, doi:10.1097/00000441-200310000-00015.
[36]  Judge, K.; Bauld, L.; Chesterman, J.; Ferguson, J. The English smoking treatment services: Short-term outcomes. Addiction 2005, 100, 46–58.
[37]  Schnoll, R.A.; Patterson, F. Sex heterogeneity in pharmacogenetic smoking cessation clinical trials. Drug Alcohol Depend. 2009, 104, S94–S99, doi:10.1016/j.drugalcdep.2008.11.012.
[38]  Lumley, J.; Chamberlain, C.; Dowswell, T.; Oliver, S.; Oakley, L.; Watson, L. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst. Rev. 2009, 8, doi:10.1002/14651858.CD001055.pub3.
[39]  Pisinger, C.; Vestbo, J.; Borch-Johnsen, K.; Thomsen, T.; J?rgensen, T. Acceptance of the smoking cessation intervention in a large population-based study: The Inter99 study. Scand. J. Public Health 2005, 33, 138–145, doi:10.1080/14034940410028370.
[40]  Batra, A. Treatment of tobacco dependence. Deutsches ?rzteblatt Int. 2011, 108, 555–564.
[41]  Fidler, J.A.; Shahab, L.; West, R. Strength of urges to smoke as a measure of severity of cigarette dependence: Comparison with the Fagerstr?m Test for Nicotine Dependence and its components. Addiction 2011, 106, 631–638, doi:10.1111/j.1360-0443.2010.03226.x.
[42]  Li, M.D.; Cheng, R.; Ma, J.Z.; Swan, G.E. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 2003, 98, 23–31, doi:10.1046/j.1360-0443.2003.00295.x.
[43]  Tate, J.C.; Pomerleau, C.S.; Pomerleau, O.F. Pharmacological and non-pharmacological smoking motives: A replication and extension. Addiction (Abingdon, England) 1994, 89, 321–330, doi:10.1111/j.1360-0443.1994.tb00899.x.
[44]  Uhl, G.R.; Drgon, T.; Li, C.-Y.; Johnson, C.; Liu, Q.-R. Smoking and smoking cessation in disadvantaged women: Assessing genetic contributions. Drug Alcohol Depend. 2009, 104, S58–S63, doi:10.1016/j.drugalcdep.2009.03.012.
[45]  Le Strat, Y.; Rehm, J.; Le Foll, B. How generalisable to community samples are clinical trial results for treatment of nicotine dependence: A comparison of common eligibility criteria with respondents of a large representative general population survey. Tob. Control 2011, 20, 338–343, doi:10.1136/tc.2010.038703.
[46]  Baha, M.Y.; Le Faou, A.-L. Smoking cessation interventions offered to French adult light smokers: A heterogeneous population with specific needs. Eur. Add. Res. 2010, 16, 162–169, doi:10.1159/000314360.
[47]  Schuurmans, M.M.; Diacon, A.H.; van Biljon, X.; Bolliger, C.T. Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: A randomized controlled trial. Addiction 2004, 99, 634–640, doi:10.1111/j.1360-0443.2004.00711.x.
[48]  Carlson, L.E.; Taenzer, P.; Koopmans, J.; Bultz, B.D. Eight-year follow-up of a community-based large group behavioral smoking cessation intervention. Add. Behav. 2000, 25, 725–741, doi:10.1016/S0306-4603(00)00081-2.


comments powered by Disqus